These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 11737084)

  • 1. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.
    Gniadkowski M
    Clin Microbiol Infect; 2001 Nov; 7(11):597-608. PubMed ID: 11737084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of β-Lactamase-Producing Pathogens.
    Bush K; Bradford PA
    Clin Microbiol Rev; 2020 Mar; 33(2):. PubMed ID: 32102899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Appearance of extended-spectrum beta-lactamases].
    Iyobe S
    Nihon Rinsho; 1997 May; 55(5):1219-24. PubMed ID: 9155178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology.
    Ghafourian S; Sadeghifard N; Soheili S; Sekawi Z
    Curr Issues Mol Biol; 2015; 17():11-21. PubMed ID: 24821872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beta-lactamases with a wide substrate spectrum in gram negative strictly anaerobic rods].
    Rokosz A; Sawicka-Grzelak A; Kot K; Pituch H; Meisel-Mikołajczyk F; Luczak M
    Med Dosw Mikrobiol; 2000; 52(2):129-37. PubMed ID: 11107787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's new in antibiotic resistance? Focus on beta-lactamases.
    Babic M; Hujer AM; Bonomo RA
    Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamases: an actual problem of hospital microbiology (a review).
    Szabó D; Barcs I; Rozgonyi F
    Acta Microbiol Immunol Hung; 1997; 44(4):309-25. PubMed ID: 9554165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of extended-spectrum beta-lactamases by mutation.
    Gniadkowski M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():11-32. PubMed ID: 18154525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extended-spectrum beta-lactamases: their role in clinical microbiology laboratory, treatment and infection control].
    Dolapçi I
    Mikrobiyol Bul; 2005 Apr; 39(2):229-40. PubMed ID: 16128036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
    Gutkind GO; Di Conza J; Power P; Radice M
    Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and drug resistance pattern of extended spectrum β-lactamases (ESBLs) producing Enterobacteriaceae in Africa.
    Saravanan M; Ramachandran B; Barabadi H
    Microb Pathog; 2018 Jan; 114():180-192. PubMed ID: 29196174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant Acinetobacter baumannii in Egypt.
    Said HS; Benmahmod AB; Ibrahim RH
    World J Microbiol Biotechnol; 2018 Dec; 34(12):189. PubMed ID: 30511216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.
    Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V
    Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.